Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

According to SNS Insider, the global RNAi Technology Market was valued at USD 3.02 billion in 2024 and is projected to reach USD 9.03 billion by 2032, expanding at a CAGR of 14.68% over 2025–2032. RNA ...

New York, May 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global RNA Interference Technology Market - Premium Insight, Competitive News Feed Analysis, Company ...

Lethal and rescuer genes are defined as genes that when inactivated result in cell death or enhanced cell growth, respectively. The ability to identify these genes in large-scale automated screening ...

RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi therapeutics, today announced it is expanding its ongoing Phase 1 study of DCR-MYC ...

SanegeneBio has formed a worldwide research and licensing partnership with Eli Lilly and Company to develop RNAi [RNA interference] candidates for metabolic diseases. These candidates will be ...

Farmers looking to gain the upper hand over corn rootworm (CRW) pests have new tools to deploy in the field, thanks to Ribonucleic acid interference (RNAi) technology. RNAi works in CRW as it feeds on ...

Innatrix‘s lead product, InnaNema, targets soybean cyst nematode, one of the most damaging pests for U.S. soybean crops.